Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

@article{Maccallum2005SeliciclibR,
  title={Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.},
  author={D E Maccallum and Jean Melville and Sheelagh Frame and Kathryn A. Watt and Sian Anderson and Athos Gianella-Borradori and D. P. Lane and Simon R Green},
  journal={Cancer research},
  year={2005},
  volume={65 12},
  pages={5399-407}
}
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the kinase. It has greatest activity against CDK2/cyclin E, CDK7/cyclin H, and CDK9/cyclin T. Seliciclib induces apoptosis from all phases of the cell cycle in tumor cell lines, reduces tumor growth in xenografts in nude mice and is currently in phase II clinical trials. This study investigated the mechanism of cell death in multiple myeloma cells treated with seliciclib. In… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 120 extracted citations

Roscovitine ameliorates endotoxin-induced uveitis through neutrophil apoptosis

Molecular medicine reports • 2016
View 4 Excerpts
Highly Influenced

Seliciclib in malignancies.

Expert opinion on investigational drugs • 2009
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Live or let die: the cell's response to p53

Nature Reviews Cancer • 2002
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…